Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 11, Issue 5, Pages 248-249Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2014.64
Keywords
-
Categories
Ask authors/readers for more resources
The final analysis of the MSLT-1 trial confirms that sentinel lymph node biopsy (SNLB) does not improve survival in patients with melanoma > 1 mm thickness. Subgroup analyses remain inconclusive. SNLB provides prognostic information for adjuvant therapy decisions, as recent data indicate that adjuvant therapies are effective in patients with positive sentinel nodes with an ulcerated primary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
